TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05814575

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEXUS intervention
Description: During the fetal ultrasound protocol, the NEXUS intervention is added for the component of 'attachment promotion' as it is a natural extension to share with the pregnant person the behavioral and social strengths of their unborn child. As the participant observes the fetus on the monitor (a second external monitor is set up for easy viewing by the mother), she may also feel fetal movement simultaneously in the womb (after 23 weeks gestation), creating a visual and sensory link between the mother and fetus. A trained nurse or ultrasonographer shares observations of fetal behavior with the mother and others if present. The nurse is also trained in motivational interviewing techniques to use the strengths of the mother and those attributed to her fetus to explore readiness to change and other motivational factors that may be barriers to health promotion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Non-Medical fetal ultrasound
Description: A standardized protocol using non-diagnostic fetal ultrasound that includes basic maternal-fetal health assessment by a trained nurse, fetal neurobehavioral assessment, measures of fetal growth, and pictures \& videos given to parents.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Non-Medical fetal ultrasound
Description: A standardized protocol using non-diagnostic fetal ultrasound that includes basic maternal-fetal health assessment by a trained nurse, fetal neurobehavioral assessment, measures of fetal growth, and pictures \& videos given to parents.
Study: NCT06348719

Intervention type: OTHER
Group type: OTHER
Intervention: Prospective cohort study
Description: A prospective cohort of patients will be set up to support the randomized controlled trial. Patients will be offered participation in this cohort if the center is unable to participate in the randomized trial (i.e., does not have a robot, or does not have a laparoscopic column with fluorescence), if the patient refuses randomization in the randomized controlled trial, if the surgeon refuses to randomize the patient, or if the surgeon does not meet the learning curve criteria required for robotic surgery. These patients will be followed in exactly the same way as patients included in the randomized controlled trial, once their consent has been obtained.
Study: NCT04666155

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Colonic Exoperistalsis with MOWOOT device
Description: Patients under the experimental arm of the study should place the belt of the Mowoot device on the abdomen and use it for 20 minutes every day for 12 weeks. They should continue with their individualized standard of care againts constipation for the first 4 weeks. During the following 8 weeks of the interventional period of 12weeks, their use of SocTAI will be considered rescue intervention. The 8weeks following the 12weeks of intervention, they can keep on using ICE device.or SocTAI or both.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of care with Trans-Anal Irrigation
Description: Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation for the 12weeks of intervention. The following 8 weeks they can keep on using SocTAI or ICE device or both.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care with Trans-Anal Irrigation
Description: Patients under the active comparator arm of the study should continue with their individualized standard of care againts constipation for the 12weeks of intervention. The following 8 weeks they can keep on using SocTAI or ICE device or both.
Study: NCT05547854

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavior Therapy Training Institute
Description: In-person therapist training will follow the Tourette Association of America's established Behavior Therapy Training Institute procedures and will consist of 12 hours of in-person training conducted over the course of 2 days. Day 1 will involve standardized didactic lectures on tic disorders and video demonstrations of therapeutic techniques. Day 2 will involve break-out groups and role-play practice of CBIT techniques. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a training instructor while providing CBIT to a study-enrolled patient.
Study: NCT05946265

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: simulation of Photobiomodulation
Description: Simulation of the use of FBM will be carried out identically to the Experimental group. The person responsible for applying the FBM will simulate irradiation by positioning the devices in the same locations described for the FBM group, however, the laser pointer will be turned off and the sound of the device will be recorded to mimic the use of the equipment and the participant will not identify the group to be used. who belongs. In this trial, we have no criteria for discontinuing or modifying allocated interventions because no harm is expected with this intervention.
Study: NCT05895344

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton-therapy
Description: Proton pencil-beam-scanning irradiation (50,4 Gy (RBE) in 28 fractions)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photon radiotherapy
Description: Intensity modulated radiotherapy with or without stereotactic positioning (50,4 Gy in 28 fractions)
Study: NCT05198609

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FOLFOX-HAIC
Description: Hepatic arterial infusion of oxaliplatin (85mg/m2,IA,day 1, hour 0-2), fluorouracil (400mg/m2,IA,day 1, hour 3), leucovorin (400mg/m2, IV,day 1, hour 2-3) and fluorouracil (2400mg/m2, IA, hour 3-23) repeated every 4 weeks for a total of six times

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab
Description: Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab was administered 200mg intravenously for 30-60 minutes every 2 weeks, and the maximum cumulative duration of Camrelizumab is 2 years. The shortest time interval between two administrations should not be less than 12 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apatinib
Description: Apatinib was administered orally 250mg once per day
Study: NCT06348719

Intervention type: OTHER
Group type: OTHER
Intervention: Retrospective cohort study
Description: Retrospective data collection from the medical records of all patients who underwent hysterectomy for low- or intermediate-risk endometrial cancer during the inclusion period at a participating center and who were not included in the randomized controlled trial or prospective cohort; up to a limit of 1000 inclusions. For this retrospective cohort, only data concerning initial age, BMI, histological type of cancer and surgical approach used will be collected.

Intervention type: OTHER
Group type: OTHER
Intervention: information and consent
Description: information and consent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: information and consent
Description: information and consent

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: information and consent
Description: information and consent

Intervention type: OTHER
Group type: OTHER
Intervention: information and consent
Description: information and consent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: randomization
Description: Randomization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: randomization
Description: Randomization

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
Description: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
Description: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
Study: NCT05198609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib was administered orally 250mg once per day
Study: NCT04972630

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pal-Care
Description: Pal-Care intervention participants will receive a 6-month intervention based upon the WHO toolkit and it will be delivered by the community health workers (CHWs). The goal of this pragmatic clinical trial is to test and evaluate a home-based palliative care intervention for utilizing community health workers to facilitate the delivery of palliative care to cancer patients in rural India. More details provided in the intervention arms section. After the intervention, clinicians, CHWs and a purposefully selected set of patients/caregivers, who were involved in the Pal-Care will be interviewed to understand their experiences, needs, expectations, barriers, facilitators and strategies.
Study: NCT05547854

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBIT-Trainer
Description: In the online therapist training condition participants will be provided with access to the CBIT-Trainer program and asked to complete the training over the course of 4 weeks. CBIT-Trainer is designed for the average user to complete in approximately 12 hours. Participants (therapists) will receive up to three, 30-minute follow-up consultations with a CBIT expert while providing CBIT to a study-enrolled patient.
Study: NCT05558254

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Robert - intervention to enhance muscle strength
Description: Intervention:~Training will be conducted with the robot ROBERT®. 3 times a week for 8 weeks the patient will conduct 60 repetitions of hip flexion of one leg. The patient is lying supine. ROBERT is attached to the patient's lower leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. The ROBERT is attached to the patient's lower leg and thereby eliminating the gravity of the leg. The physiotherapist guides the patient's leg in hip flexion and ROBERT record the movement. ROBERT is set in active or guided mode and will be individually adjusted. When practice starts the patient get visual feedback to the range of movement of the hip flexion plus the amount of repetitions conducted and persisting.
Study: NCT04972630

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control-Usual Care
Description: The control group will receive usual care palliative services in which the patient or caregiver (by proxy) must visit the Tata Medical Center (TMC) cancer center for care. TMC services include consultation with a multi-disciplinary team (oncologist, nurse, psychologist), a 21-day morphine supply at reduced cost (as morphine is regulated in use),basic training on medication usage, catheter and wound care, other topics as relevant,and psychological counseling. Patients (or their proxy) must return to the cancer center as needed for follow up care and they are provided a 24/7 hotline to call in case of emergency.
Study: NCT04973228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roflumilast Foam
Description: Roflumilast 0.3% foam for topical application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Foam
Description: Vehicle foam for topical application
Study: NCT06348719

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence
Description: Collection of socio-demographic, clinical, biological, imaging and histopathological data, treatment decision, recurrence

Intervention type: OTHER
Group type: OTHER
Intervention: Surgical data collection
Description: Surgical data collection at Day 0

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surgical data collection
Description: Surgical data collection at Day 0

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical data collection
Description: Surgical data collection at Day 0

Intervention type: OTHER
Group type: OTHER
Intervention: Biological data collection
Description: Biological data collection at Day 1

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological data collection
Description: Biological data collection at Day 1

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biological data collection
Description: Biological data collection at Day 1

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of histological data from the surgical specimen
Description: Collection of histological data from the surgical specimen et Day 42

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of histological data from the surgical specimen
Description: Collection of histological data from the surgical specimen et Day 42

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of histological data from the surgical specimen
Description: Collection of histological data from the surgical specimen et Day 42
Study: NCT04681287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: inetetamab and PD-1 inhibitor combined with chemotherapy.
Description: 1. Chemotherapy selected by doctors: albumin bound paclitaxel, vinorelbine, gemcitabine, capecitabine, and aribrin were administered according to clinical routine;~2. The first dose was 8 mg / kg, followed by 6 mg / kg, once every 3 weeks~3. PD-1 inhibitor 200mg D1 every 3 weeks as a cycle Treatment to disease progression or toxicity intolerance, or death from any cause.~The efficacy was evaluated every 2 cycles and adverse events were recorded. After 4-6 cycles of treatment, if the patient is intolerable to chemotherapy for any reason, the chemotherapy can be stopped and the combination of inistumab and PD-1 can be continued.
Study: NCT06348719

Intervention type: OTHER
Group type: OTHER
Intervention: Phone calls
Description: Phone calls at Day 1, Day 3,Day 7,Day14,Day 21 , Month 3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone calls
Description: Phone calls at Day 1, Day 3,Day 7,Day14,Day 21 , Month 3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Phone calls
Description: Phone calls at Day 1, Day 3,Day 7,Day14,Day 21 , Month 3

Intervention type: OTHER
Group type: OTHER
Intervention: Pain assessment
Description: Pain assessment at day 1 , Day 3,Day 7,Day14,Day 21 , Month 3

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain assessment
Description: Pain assessment at day 1 , Day 3,Day 7,Day14,Day 21 , Month 3

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain assessment
Description: Pain assessment at day 1 , Day 3,Day 7,Day14,Day 21 , Month 3

Intervention type: OTHER
Group type: OTHER
Intervention: Collect of data on non-reimbursed transport
Description: Collect of data on non-reimbursed transport at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collect of data on non-reimbursed transport
Description: Collect of data on non-reimbursed transport at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collect of data on non-reimbursed transport
Description: Collect of data on non-reimbursed transport at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6

Intervention type: OTHER
Group type: OTHER
Intervention: Collect of everyday help
Description: Collect of everyday help at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collect of everyday help
Description: Collect of everyday help at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collect of everyday help
Description: Collect of everyday help at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of the business resumption date
Description: Collection of the business resumption date at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of the business resumption date
Description: Collection of the business resumption date at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of the business resumption date
Description: Collection of the business resumption date at Day 3,Day 7,Day14,Day 21 , day 42, Month 3, month 6

Intervention type: OTHER
Group type: OTHER
Intervention: SF36 questionnaire
Description: SF36 questionnaire at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, month 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SF36 questionnaire
Description: SF36 questionnaire at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, month 6
Study: NCT05064345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HB0034
Description: Recombinant Humanized Anti-IL-36R Monoclonal antibody
Study: NCT04560309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-alanyl-L-glutamine dipeptide
Description: Intravenous infusion of 0.5 mg/kgbw L-alanyl-L-glutamine dipeptide diluted in normal saline to volume of 500 mL, started after induction of anesthesia for 24 hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion of 500 mL normal saline, started after induction of anesthesia for 24 hours.
Study: NCT06348719

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SF36 questionnaire
Description: SF36 questionnaire at inclusion, Day 3,Day 7,Day14,Day 21 , day 42, month 6
Study: NCT06348719

Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaire EQ5D-5L
Description: Questionnaire EQ5D-5L at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire EQ5D-5L
Description: Questionnaire EQ5D-5L at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire EQ5D-5L
Description: Questionnaire EQ5D-5L at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6

Intervention type: OTHER
Group type: OTHER
Intervention: FIGO Stadium
Description: FIGO Stadium at inclusion and Day 42

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIGO Stadium
Description: FIGO Stadium at inclusion and Day 42

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FIGO Stadium
Description: FIGO Stadium at inclusion and Day 42

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.)
Description: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.) at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.)
Description: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.) at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.)
Description: Collection of treatments (analgesics and anticoagulants up to J42, complication-related treatments, etc.) at day 1, Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of adjuvant treatments
Description: Collection of adjuvant treatments at month 6
Study: NCT05650307

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The magnetic field exposure for MRI in this study is similar to standard clinical MR procedures. The powers of all radio frequency fields in this study are at or under FDA guidelines. The CMR techniques performed here have been used in the literature and in our own clinical cardiac MRI service extensively for several years and have an excellent safety profile in our institution.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The magnetic field exposure for MRI in this study is similar to standard clinical MR procedures. The powers of all radio frequency fields in this study are at or under FDA guidelines. The CMR techniques performed here have been used in the literature and in our own clinical cardiac MRI service extensively for several years and have an excellent safety profile in our institution.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: The magnetic field exposure for MRI in this study is similar to standard clinical MR procedures. The powers of all radio frequency fields in this study are at or under FDA guidelines. The CMR techniques performed here have been used in the literature and in our own clinical cardiac MRI service extensively for several years and have an excellent safety profile in our institution.
Study: NCT06348719

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collection of adjuvant treatments
Description: Collection of adjuvant treatments at month 6

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collection of adjuvant treatments
Description: Collection of adjuvant treatments at month 6

Intervention type: OTHER
Group type: OTHER
Intervention: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one
Description: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one at Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one
Description: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one at Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one
Description: Recording of any complications, emergency room visits/unscheduled consultations, additional work stoppages to the initial one at Day 3,Day 7,Day14,Day 21 , day 42, month 3, month 6
Study: NCT06343532

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SXC-2023
Description: 200 mg capsules
Study: NCT06348719

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of data
Description: Collection of data on age, baseline, BMI, histological type of cancer and surgical approach used